180 Life Sciences ROCE
Was ist das ROCE von 180 Life Sciences?
ROCE von 180 Life Sciences Corp. ist 14,186.55%
Was ist die Definition von ROCE?
Die Kapitalerträge (ROCE) entsprechen einer Finanzkennzahl, die die Rentabilität eines Unternehmens und die Effizienz, mit der sein Kapital verwendet wird, misst.
Return on capital employed (ROCE) is the total amount of capital that a company has utilized in order to generate profits. It is the sum of shareholders' equity and debt liabilities. It can be simplified as total assets minus current liabilities.
ROCE is especially useful when comparing the performance of companies in capital-intensive sectors. ROCE considers debt and other liabilities as well compared to other fundamentals which only analyze profitability related to a company’s common equity. This provides a better indication of financial performance for companies with significant debt. For a company, the ROCE trend over the years is also an important indicator of performance. In general, investors tend to favor companies with stable and rising ROCE numbers over companies where ROCE is volatile and bounces around from one year to the next.
Instead of using capital employed at an arbitrary point in time, analysts and investors often calculate ROCE based on the average capital employed (ROACE), which takes the average of opening and closing capital employed for the time period.
ROCE von Unternehmen in Health Care Sektor auf NASDAQ im Vergleich zu 180 Life Sciences
Was macht 180 Life Sciences?
180 Life Sciences Corp., a clinical-stage biotechnology company, engages in the development of novel drugs for unmet medical needs in chronic pain, inflammation, inflammatory diseases, and fibrosis. Its product development platforms in Phase IIb/III clinical trials include Fibrosis and anti-tumour necrosis factor (Anti-TNF) platform, which focuses on fibrosis and Anti-TNF; Synthetic Cannabidiol (CBD) Analogs platform, which are man-made derivatives of CBD; and a7nAChR platform, which focuses on alpha 7 nicotinic acetylcholine receptor. The company was incorporated in 2016 and is headquartered in Palo Alto, California.
Unternehmen mit roce ähnlich 180 Life Sciences
- Blue Apron Inc hat ROCE von 5,016.13%
- ParkerVision hat ROCE von 5,589.92%
- Asensus Surgical Inc hat ROCE von 5,861.92%
- Whiting USA Trust II hat ROCE von 7,251.43%
- Astra hat ROCE von 7,618.05%
- Kalo Gold hat ROCE von 8,333.61%
- 180 Life Sciences hat ROCE von 14,186.55%
- Ideanomics Inc hat ROCE von 29,881.71%
- Internet Gold - Golden Lines hat ROCE von 31,538.46%
- Predictiv Ai Inc hat ROCE von 33,476.12%
- T2 Biosystems Inc hat ROCE von 56,826.92%
- AMBG hat ROCE von 145,496.28%
- Woluwe Shopping Center hat ROCE von 520,618,500.00%